Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma

被引：0
|
作者：
Meena N. Murugappan
Bellinda L. King-Kallimanis
Vishal Bhatnagar
Bindu Kanapuru
Joel F. Farley
Randall D. Seifert
David D. Stenehjem
Ting-Yu Chen
Erica G. Horodniceanu
Paul G. Kluetz
机构：
[1] U.S. Food and Drug Administration (U.S. FDA),Office of Oncologic Diseases, Center for Drug Evaluation and Research (CDER)
[2] LUNGevity Foundation,Center for Drug Evaluation and Research (CDER)
[3] Oncology Center for Excellence (U.S. FDA),Department of Pharmaceutical Care and Health Systems
[4] U.S. Food and Drug Administration (U.S. FDA),Department of Pharmacy Practice and Pharmaceutical Sciences
[5] University of Minnesota – College of Pharmacy,undefined
[6] University of Minnesota – College of Pharmacy,undefined
[7] Oncology Center of Excellence,undefined
[8] Food and Drug Administration,undefined
来源：
Quality of Life Research | 2023年 / 32卷
关键词：
Patient-reported outcomes; Frailty; Multiple myeloma; Geriatric oncology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2281 / 2292
页数：11
相关论文
共 50 条
  • [31] Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma
    Abuhelwa, Ahmad Y.
    Almansour, Sara A.
    Basch, Ethan
    Al-Shamsi, Humaid O.
    Abuhelwa, Ziad
    Bustanji, Yasser
    Semreen, Mohammad H.
    Kharaba, Zelal
    Ali, Salma M.
    Mohamed, Rawan
    Kichenadasse, Ganessan
    Mckinnon, Ross A.
    Sorich, Michael J.
    Alzoubi, Karem H.
    Hopkins, Ashley M.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025,
  • [32] Patient-reported measures of well-being in older multiple myeloma patients: use of secondary data source
    Irena Cenzer
    Karin Berger
    Annette M. Rodriguez
    Helmut Ostermann
    Kenneth E. Covinsky
    Aging Clinical and Experimental Research, 2020, 32 : 1153 - 1160
  • [33] How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review
    Matthew R. LeBlanc
    Rachel Hirschey
    Ashley Leak Bryant
    Thomas W. LeBlanc
    Sophia K. Smith
    Quality of Life Research, 2020, 29 : 1419 - 1431
  • [34] Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
    Judith J Stephenson
    David M Kern
    Sonalee S Agarwal
    Ruth Zeidman
    Krithika Rajagopalan
    Siddhesh A Kamat
    John Foley
    Health and Quality of Life Outcomes, 10
  • [35] Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study
    Lerede, Annalaura
    Rodgers, Jeff
    Middleton, Rod M.
    Hampshire, Adam
    Nicholas, Richard
    BRAIN COMMUNICATIONS, 2023, 5 (04)
  • [36] Measuring patients' views: a bifactor model of distinct patient-reported outcomes in psychosis
    Reininghaus, U.
    McCabe, R.
    Burns, T.
    Croudace, T.
    Priebe, S.
    PSYCHOLOGICAL MEDICINE, 2011, 41 (02) : 277 - 289
  • [37] A Prognostic Symptom Model Incorporating Patient-Reported Symptoms for Transplant-Ineligible Patients with Multiple Myeloma
    Balitsky, Amaris K.
    Sutradhar, Rinku
    Seow, Hsien
    Gayowsky, Anastasia
    Visram, Alissa
    Tay, Jason
    Sandhu, Irwindeep
    Mian, Hira
    CANCERS, 2025, 17 (03)
  • [38] Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
    Stephenson, Judith J.
    Kern, David M.
    Agarwal, Sonalee S.
    Zeidman, Ruth
    Rajagopalan, Krithika
    Kamat, Siddhesh A.
    Foley, John
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2012, 10
  • [39] Patient-reported outcomes (PRO's) in glaucoma: a systematic review
    Vandenbroeck, S.
    De Geest, S.
    Zeyen, T.
    Stalmans, I.
    Dobbels, F.
    EYE, 2011, 25 (05) : 555 - 577
  • [40] Patient-reported outcomes (PRO's) in glaucoma: a systematic review
    S Vandenbroeck
    S De Geest
    T Zeyen
    I Stalmans
    F Dobbels
    Eye, 2011, 25 : 555 - 577
12345